Navigation Links
Adnexus Therapeutics Announces Presentation at the American,Association for Cancer Research (AACR) on Clinical Product,Candidate, CT-322

WALTHAM, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Adnexus(TM) Therapeutics, Inc. today announced the presentation of the abstract "CT-322: A specific VEGFR-2-blocking protein therapeutic agent with activity in preclinical tumor models comparable to pan-specific tyrosine kinase receptor inhibitors sunitinib and sorafenib" at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles, CA. The lead author is Irvith Carvajal, Ph.D., with Eric Furfine, Ph.D., senior vice president of research and preclinical development at Adnexus, presenting at the meeting.

CT-322 is a mono-specific blocker of the tyrosine kinase receptor, VEGFR-2, and blocks its activation by all known extracellular ligands; VEGF-A, VEGF-C, and VEGF-D. VEGFR-2 activation is the primary driver of tumor angiogenesis. In preclinical tumor models, CT-322 was compared to two approved pan-kinase inhibitors sunitinib and sorafenib. CT-322, sunitinib, and sorafenib each demonstrated comparable tumor growth suppression; however, CT-322 was better tolerated in the animal models.

"Our results suggest that 'pan-specific' kinase inhibitors may not offer improvement in anti-angiogenic induced tumor suppression over an extracellular, mono-specific blocker of VEGFR-2," commented Dr. Furfine. "CT-322's high affinity and selectivity for VEGFR-2 achieved comparable anti-tumor effect to molecules that inhibit a broad range of kinases."

"As cancer therapy evolves, the importance of efficacy, safety and tolerability of anti-angiogenic agents are becoming more pronounced due to the desire for combination therapy as well as longer duration of anti-angiogenic therapy," commented John Mendlein, Ph.D., chief executive officer of Adnexus. "We continue to extend our understanding of the VEGFR-2 pathway in tumor settings and its activation by VEGF-A, C and D. We are very encouraged by the emerging CT-322 Phase 1 data, and we look forward to evaluating CT-322 in Phase 2 later this year."

CT-322 is currently in Phase 1 clinical development in oncology in the United States, and in February 2007 Adnexus announced interim results of an ongoing Phase 1 open-label, dose-escalation study in patients with advanced cancers. In those interim results, CT-322 demonstrated promising evidence of biological activity in patients within four hours of drug administration as evidenced by elevated plasma levels of biomarkers associated with blockade of VEGFR-2. These biomarkers remained elevated significantly above baseline throughout the treatment period. In addition, CT-322 administration resulted in predictable, consistent pharmacokinetics that could support every-other-week dosing in humans.

Abstract Number: 4189

About the Adnectin Product Class and the PROfusion System

Adnectins are an emerging protein therapeutic class that can be designed to treat a broad range of diseases. They are based on human fibronectin, an extracellular protein that is naturally abundant in human serum. The intrinsic properties of an Adnectin align with properties of successful drugs, including high potency, specificity, stability, favorable half life, favorable IP profile and high yield E. coli production.

Adnectins are designed using the PROfusion System, Adnexus' patented protein design engine, to achieve high potency and specificity for a therapeutic target while simultaneously selecting for ideal pharmaceutical product characteristics. PROfusion enables Adnexus to screen over 1 trillion unique Adnectins for each drug discovery program to "redirect" naturally occurring human fibronectin to act as a protein therapeutic. This greatly accelerates Adnectin drug discovery and development.

Adnexus is the exclusive developer of Adnectins. Adnexus solely owns the Adnectin patent estate that controls issued and pending patent properties to fundamental Adnectin forms. In addition, Adnexus exclusively co ntrols its patented PROfusion protein design engine. Adnexus has over 100 issued and pending patent properties relating to Adnectins and PROfusion.

About Adnexus Therapeutics

Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of its broadly applicable new therapeutic class, Adnectins. Adnexus' lead product candidate, CT-322, is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that uniquely enables rapid optimization of protein therapeutics. The company is funded by four leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, and Venrock Associates.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

Adnectin(TM), Adnexus(TM) Therapeutics and PROfusion(TM) are trademarks of Adnexus(TM) Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus(TM) Therapeutics.

For more information, please visit www.adnexustx.com

Contact

Corporate Contacts
Adnexus Therapeutics, Inc.
Katrine Bosley, 781-891-3745
Vice President Business Development
pr@adnexustx.com
or
Media Contacts
Feinstein Kean Healthcare
Krystle Ficco, 617-761-6702
krystle.ficco@fkhealth.com


'"/>




Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is excited ... their Miami dental office. Beginning in January, Miami Dental Specialists will offer the non-metal ... are the first office to be chosen by the dental implant manufacturer, Straumann, to ...
(Date:2/12/2016)... ... 12, 2016 , ... Nearly every health website and vision ... articles generally list between five and 15 foods that should be consumed regularly ... of these lists and believes that nutritious eye healthy foods are extremely important, ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... the real facts surrounding all those Bible stories. For generations families have gathered to ... Yisrayl says there is more to these than just mere “stories”. , The ...
(Date:2/12/2016)... ... ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of the ... licensed under Dignity Health Arizona General Hospital , which opened last year in ... our new freestanding emergency room delivers the highest quality care to Mesa and the ...
Breaking Medicine News(10 mins):